Platinum chemotherapy is a valid treatment option in patients with BRCA mutations, according to investigators. This is the first analysis to compare efficacy of PARP inhibitors, platinum in BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).
The team of researchers from Stanford University and Italy concluded that "men diagnosed with insomnia only were found to have a higher risk of developing ED."